163 related articles for article (PubMed ID: 2242423)
1. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin.
Zehnder JL; Leung LL
Blood; 1990 Nov; 76(10):2011-6. PubMed ID: 2242423
[TBL] [Abstract][Full Text] [Related]
2. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
Lo CY; Jones C; Glader B; Zehnder JL
Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
[TBL] [Abstract][Full Text] [Related]
3. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V.
Bänninger H; Hardegger T; Tobler A; Barth A; Schüpbach P; Reinhart W; Lämmle B; Furlan M
Br J Haematol; 1993 Nov; 85(3):528-32. PubMed ID: 8136275
[TBL] [Abstract][Full Text] [Related]
4. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin.
Israels SJ; Israels ED
Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):249-54. PubMed ID: 8037345
[TBL] [Abstract][Full Text] [Related]
5. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
[TBL] [Abstract][Full Text] [Related]
6. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin.
Tarantino MD; Ross MP; Daniels TM; Nichols WL
J Pediatr Hematol Oncol; 1997; 19(3):226-31. PubMed ID: 9201145
[TBL] [Abstract][Full Text] [Related]
7. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin.
Su Z; Izumi T; Thames EH; Lawson JH; Ortel TL
J Lab Clin Med; 2002 Jun; 139(6):349-56. PubMed ID: 12066133
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
Chouhan VD; De La Cadena RA; Nagaswami C; Weisel JW; Kajani M; Rao AK
Thromb Haemost; 1997 Feb; 77(2):343-9. PubMed ID: 9157594
[TBL] [Abstract][Full Text] [Related]
9. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases.
Spero JA
J Neurosurg; 1993 May; 78(5):817-20. PubMed ID: 8468613
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin.
Rapaport SI; Zivelin A; Minow RA; Hunter CS; Donnelly K
Am J Clin Pathol; 1992 Jan; 97(1):84-91. PubMed ID: 1728869
[TBL] [Abstract][Full Text] [Related]
11. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin.
Neschis DG; Heyman MR; Cheanvechai V; Benjamin ME; Flinn WR
J Vasc Surg; 2002 Feb; 35(2):400-2. PubMed ID: 11854743
[TBL] [Abstract][Full Text] [Related]
12. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin.
Muntean W; Zenz W; Edlinger G; Beitzke A
Thromb Haemost; 1997 Jun; 77(6):1223. PubMed ID: 9241765
[No Abstract] [Full Text] [Related]
13. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
Savage WJ; Kickler TS; Takemoto CM
Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
[TBL] [Abstract][Full Text] [Related]
14. Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding.
Ajzner E; Balogh I; Haramura G; Boda Z; Kalmár K; Pfliegler G; Dahlbäck B; Muszbek L
J Thromb Haemost; 2003 May; 1(5):943-9. PubMed ID: 12871359
[TBL] [Abstract][Full Text] [Related]
15. Cross-reactivity of rabbit anti-bovine prothrombin/thrombin IgGs with bovine factor V/Va-related antigens.
He Zhu ; Hoppensteadt D; Morris M; Fareed J
Clin Appl Thromb Hemost; 2010 Oct; 16(5):522-8. PubMed ID: 20699260
[TBL] [Abstract][Full Text] [Related]
16. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery.
Flaherty MJ; Henderson R; Wener MH
Ann Intern Med; 1989 Oct; 111(8):631-4. PubMed ID: 2802417
[TBL] [Abstract][Full Text] [Related]
17. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant.
Zumberg MS; Waples JM; Kao KJ; Lottenberg R
Am J Hematol; 2000 May; 64(1):59-63. PubMed ID: 10815789
[TBL] [Abstract][Full Text] [Related]
18. Perioperative evaluation of bleeding diathesis.
Leung LL
Hematology Am Soc Hematol Educ Program; 2006; ():457-61. PubMed ID: 17124099
[TBL] [Abstract][Full Text] [Related]
19. Risk and clinical significance of developing antibodies induced by topical thrombin preparations.
Dorion RP; Hamati HF; Landis B; Frey C; Heydt D; Carey D
Arch Pathol Lab Med; 1998 Oct; 122(10):887-94. PubMed ID: 9786349
[TBL] [Abstract][Full Text] [Related]
20. A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins.
Ofosu FA; Crean S; Reynolds MW
Clin Ther; 2009 Apr; 31(4):679-91. PubMed ID: 19446142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
